Oarsman Capital Inc. Buys 554 Shares of Bristol-Myers Squibb (NYSE:BMY)

Oarsman Capital Inc. grew its position in Bristol-Myers Squibb (NYSE:BMY) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,021 shares of the biopharmaceutical company’s stock after purchasing an additional 554 shares during the quarter. Oarsman Capital Inc.’s holdings in Bristol-Myers Squibb were worth $1,438,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Johnson Investment Counsel Inc. increased its position in Bristol-Myers Squibb by 0.7% during the third quarter. Johnson Investment Counsel Inc. now owns 127,714 shares of the biopharmaceutical company’s stock worth $7,412,000 after acquiring an additional 852 shares during the period. Excalibur Management Corp increased its holdings in shares of Bristol-Myers Squibb by 5.8% during the third quarter. Excalibur Management Corp now owns 21,037 shares of the biopharmaceutical company’s stock worth $1,221,000 after purchasing an additional 1,161 shares during the period. Financial Engines Advisors L.L.C. acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $241,000. Rafferty Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 7.6% in the third quarter. Rafferty Asset Management LLC now owns 224,040 shares of the biopharmaceutical company’s stock valued at $13,003,000 after buying an additional 15,770 shares during the period. Finally, QRG Capital Management Inc. acquired a new stake in Bristol-Myers Squibb during the third quarter worth approximately $30,399,000. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. BMO Capital Markets reduced their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Barclays decreased their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 23rd. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $41.45 on Friday. The stock’s 50-day moving average is $44.70 and its 200-day moving average is $48.79. Bristol-Myers Squibb has a 1-year low of $39.91 and a 1-year high of $66.38. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 EPS. Sell-side analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.